ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 914,65
-0,88%
Dow Jones
38 225,66
0,85%
DAX
17 896,50
-0,14%
Brent Oil
83,775
0,17%
Bitcoin
59 096,20
-0,04%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Reata Pharmaceuticals Inc (RETA)

  7. Reata Pharmaceuticals Inc (RETA) Actualités

RETA Reata Pharmaceuticals Inc

172,36
0,00 (0,00%)
Après les heures de négociation
Dernière mise à jour : 02:00:00
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Reata Pharmaceuticals Inc RETA NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,00 0,00% 172,36 02:00:00
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
172,36 172,36
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
06/10/202322:07EDGAR2Form 15-12G - Securities registration termination [Section..
28/9/202322:30EDGAR2Form SC 13D/A - General statement of acquisition of..
27/9/202301:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/9/202323:25EDGAR2Form 8-K - Current report
26/9/202322:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/9/202322:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/9/202322:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/9/202322:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/9/202322:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/9/202322:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/9/202322:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/9/202322:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/9/202322:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/9/202322:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/9/202322:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/9/202322:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/9/202322:25EDGAR2Form POSASR - Post-effective Amendment to an automatic shelf..
26/9/202322:23EDGAR2Form S-8 POS - Securities to be offered to employees in..
26/9/202314:59GLOBEBiogen Completes Acquisition of Reata Pharmaceuticals
21/9/202322:05EDGAR2Form 8-K - Current report
21/9/202316:08BWReata Pharmaceuticals Stockholders Approve Merger..
18/9/202323:34EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/9/202322:26EDGAR2Form 144 - Report of proposed sale of securities
12/9/202319:20EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
12/9/202319:16EDGAR2Form 8-K - Current report
07/9/202322:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/9/202322:09EDGAR2Form 144 - Report of proposed sale of securities
05/9/202322:08EDGAR2Form 144 - Report of proposed sale of securities
22/8/202314:00EDGAR2Form DEFM14A - Definitive proxy statement relating to merger..
17/8/202322:43EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/8/202322:40EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/8/202322:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/8/202322:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/8/202323:04EDGAR2Form 144 - Report of proposed sale of securities
16/8/202323:03EDGAR2Form 144 - Report of proposed sale of securities
16/8/202322:55EDGAR2Form 144 - Report of proposed sale of securities
16/8/202322:54EDGAR2Form 144 - Report of proposed sale of securities
16/8/202322:53EDGAR2Form 144 - Report of proposed sale of securities
16/8/202301:38EDGAR2Form 144 - Report of proposed sale of securities
16/8/202301:32EDGAR2Form 144 - Report of proposed sale of securities
16/8/202301:12EDGAR2Form 144 - Report of proposed sale of securities
11/8/202322:38EDGAR2Form PREM14A - Preliminary proxy statements relating to..
01/8/202323:17EDGAR2Form SC 13D/A - General statement of acquisition of..
01/8/202322:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/8/202322:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/8/202322:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/8/202322:29EDGAR2Form 4 - Statement of changes in beneficial ownership of..
31/7/202313:20IHMARKETNEWSMonday’s Wall Street Highlights: Palantir Technologies,..
31/7/202313:05EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
31/7/202313:01EDGAR2Form 8-K - Current report

Dernières Valeurs Consultées

NASDAQ
RETA
Reata Pharmaceuticals
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés